Decode the G‑BA
with MBM Future Health
♣ Ensure that patients receive the best possible treatment.
♣ Achieve a fair reimbursement for your medicine.
♣ Reach your full potential in the AMNOG procedure.
♣ Ultimately, rely on my long-standing experience at the G‑BA. ♣
Identifying the best clinical development strategy for innovative medicines is extremely challenging.
Uncertainty increases when evidence is scarce – often in rare diseases and precision medicine. What is the best value proposition for future reimbursement in Germany?
♣ Together with you, I identify the best scenario to ensure optimum results for your medicine. ♣
Launching a product in Germany is a critical task.
Procedures at the G-BA are complex. Decision-making authorities are difficult to understand. How to make an informed decision on your individual case with your team?
Your unique benefits
G-BA Expertise
You benefit from my long-standing experience as G-BA Officer.
Your Personal Expert
You receive advice solely from me personally.
Lean Operations
You align your efforts with G‑BA expectations.
High Value
Your resources are allocated effectively.
Orphan Drug Specialist
You improve outcomes for your innovative medicines.
Operating Worldwide
You receive in-person advice wherever you are located.
About
Meriem Bouslouk-Marx, MBM Future Health
Dr. Meriem Bouslouk-Marx
♣ First-hand Experience at the G-BA
♣ Reimbursement of Medicines
♣ Medical background
♣ Scientific Consultations
♣ Wide Range of Therapeutic Areas
♣ Specialisation in Orphan Drugs
♣ Cell and Gene Therapy
♣ International Public Health
♣ Multilingual
♣ Public Speaker
Coming together is a beginning.
Keeping together is progress.
Working together is success.
Henry Ford